Compare · AXGN vs INMD
AXGN vs INMD
Side-by-side comparison of Axogen Inc. (AXGN) and InMode Ltd. (INMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and INMD operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.20B, about 2.6x INMD ($855.3M).
- Over the past year, AXGN is up 299.2% and INMD is down 7.2% - AXGN leads by 306.4 points.
- INMD has been more active in the news (5 items in the past 4 weeks vs 1 for AXGN).
- INMD has more recent analyst coverage (20 ratings vs 8 for AXGN).
- Company
- Axogen Inc.
- InMode Ltd.
- Price
- $41.48-3.13%
- $13.51-0.11%
- Market cap
- $2.20B
- $855.3M
- 1M return
- -4.49%
- -2.95%
- 1Y return
- +299.23%
- -7.21%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 1
- 5
- Recent ratings
- 8
- 20
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Latest AXGN
- The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
- Director Wendell Amy Mcbride exercised 1,647 shares at a strike of $14.85 and sold $70,162 worth of shares (1,647 units at $42.60) (SEC Form 4)
- Director Johnson John sold $477,968 worth of shares (11,050 units at $43.26) and exercised 11,050 shares at a strike of $7.04 (SEC Form 4)
- Director Weiler Kathy Johnson exercised 16,344 shares at a strike of $6.95 and sold $720,623 worth of shares (16,344 units at $44.09) (SEC Form 4)
- Chief Marketing Officer Kemp Jens sold $173,761 worth of shares (4,000 units at $43.44), decreasing direct ownership by 5% to 72,451 units (SEC Form 4)
- CFO Hartley Lindsey Marie sold $45,897 worth of shares (1,051 units at $43.67) and exercised 5,463 shares at a strike of $8.24, increasing direct ownership by 7% to 65,146 units (SEC Form 4)
- Sales VP Quackenbush Doris sold $168,720 worth of shares (3,878 units at $43.51), decreasing direct ownership by 4% to 92,416 units (SEC Form 4)
- New insider Quackenbush Doris claimed ownership of 96,294 shares (SEC Form 3)
- TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
- Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
Latest INMD
- After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
- New insider Moshe Itzkovich claimed ownership of 7,503 units of Ordinary Shares (SEC Form 3)
- New insider Nass Shlomo claimed no ownership of stock in the company (SEC Form 3)
- SEC Form 6-K filed by InMode Ltd.
- InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer
- InMode to Present at Upcoming Investor Conferences and Events
- InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year Increase
- SEC Form 6-K filed by InMode Ltd.
- InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
- InMode to Present at the 25th Annual Needham Virtual Healthcare Conference